Otsuka Pharmaceutical Development and Commercialization

FunderResearch funding and supported work

Otsuka Pharmaceutical Development and Commercialization is a funder indexed in ScholarIQ from OpenAlex. ScholarIQ records 269 works.

269

Works

IDs:OpenAlex

What are the most-cited papers on Otsuka Pharmaceutical Development and Commercialization?

ScholarIQmost cited works

CKD progression, kidney failure, and mortality among US patients with IgA nephropathy

John J. Sim, Qiaoling Chen, Nancy Cannizzaro, Ancilla W. Fernandes, Cibele S. Pinto, Simran K. Bhandari, John Chang, Asher D. Schachter, Mohit Mathur

Nephrology Dialysis Transplantation. 202527 CitationsOPEN ACCESS

Incidence and Proportion of Primary Focal Segmental Glomerulosclerosis (FSGS) among a Racially and Ethnically Diverse Adult Patient Population between 2010 and 2021

Mercedes A. Munis, Qiaoling Chen, Matt Hill, Min Zhuo, Asher D. Schachter, Simran K. Bhandari, Aviv Hever, Teresa N. Harrison, Ancilla W. Fernandes, John J. Sim

Clinical Journal of the American Society of Nephrology. 20249 CitationsOPEN ACCESS

Mortality risk in patients with autosomal dominant polycystic kidney disease

Deirdre Mladsi, Xiaolei Zhou, Gregory Mader, Myrlene Sanon, Jinyi Wang, Christine Barnett, Cynthia Willey, Stephen L. Seliger

BMC Nephrology. 20247 CitationsOPEN ACCESS

The incidence and prevalence of immunoglobulin A nephropathy in the United States

Marc DeCongelio, Sarah Ali, Martina Furegato, Sandipan Bhattacharjee, Ancilla W. Fernandes

Clinical Nephrology. 20245 CitationsOPEN ACCESS

Patient-Reported Outcomes Measures, Polycystic Kidney Disease Burden, and Outcomes in Autosomal Dominant Polycystic Kidney Disease

Dorothee Oberdhan, Aaron Yarlas, Jakob Bue Bjørner, Holly B. Krasa

Kidney Medicine. 20234 CitationsOPEN ACCESS